# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: K060968   
B. Purpose for Submission: New Device   
C. Measurand: Prothrombin Time (PT) Activated Partial Thromboplastin Time (APTT) Fibrinogen   
D. Type of Test: Quantitative, mechanical and photo-optical   
E. Applicant: Wortham Laboratories, Inc.   
F. Proprietary and Established Names:

Stasis 1 Coagulation Control (Normal) Stasis 2 Coagulation Control (Abnormal) Stasis 3 Coagulation Control (Abnormal)

Serathan-A PT Reagent Serathan-B PT Reagent

Intrin-SI APTT Reagent Intrin-EA APTT Reagent Calcium Chloride Solution 0.02 M

Fibrinogen Control Plasma Normal   
Fibrinogen Control Plasma Low   
Fibrinogen Buffer   
Thrombin Reagent

Fibrinogen Assay Set

Heparin Control Plasma Level 1   
Heparin Control Plasma Level 2

# G. Regulatory Information:

1. Regulation section:

21 CFR 864.5425, Plasma, Coagulation Control   
21 CFR 864.7750, Prothrombin Time Test   
21 CFR 864.7925, Activated Partial Thromboplastin Time   
21 CFR 864.7340, Fibrinogen Determination System

2. Classification:

Class II

3. Product code:

GIZ, Plasma, Control, Normal GGC, Plasma Control, Abnormal GGN, Plasma, Coagulation Control GJS, Test, Time, Prothrombin GFO, Activated, Test, Thromboplastin GIL Plasma, Fibrinogen Control KQJ, System, Fibrinogen Determination

4. Panel:

81 (Hematology)

# H. Intended Use:

1. Intended use(s):

Stasis 1 Coagulation Control (Normal) is intended for use as a quality control to monitor the performance of Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) and Fibrinogen assays. It will yield PT, APTT, and Fibrinogen values in the normal range.

Stasis 2 Coagulation Control (Abnormal) is intended for use as a quality control to monitor the performance of Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT). It will yield PT, and APTT values in the moderate abnormal range.

Stasis 3 Coagulation Control (Abnormal) is intended for use as a quality control to monitor the performance of Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT). It will yield PT, and APTT values in the strongly abnormal range.

Serathan-A PT reagent is an in-vitro diagnostic reagent intended in a clinical laboratory for the quantitative determination of Prothrombin Time (PT) testing for the detection of coagulation abnormalities in the extrinsic pathway. Serathan-A is a highly sensitive thromboplastin reagent.

Serathan-B PT reagent is an in-vitro diagnostic reagent intended in a clinical laboratory for the quantitative determination of Prothrombin Time (PT) testing for the detection of coagulation abnormalities in the extrinsic pathway. Serathan-B is a moderately sensitive thromboplastin reagent.

Intrin-EA APTT is an in-vitro diagnostic reagent used in the clinical laboratory for the quantitative determination of Activated Partial Thromboplastin Time (APTT) testing for the detection of coagulation abnormalities in the intrinsic pathway. Intrin-EA reagent is sensitive to mild coagulopathies.

Intrin-SI is an in-vitro diagnostic reagent used in the clinical laboratory for the quantitative determination of Activated Partial Thromboplastin Time (APTT) testing for the detection of coagulation abnormalities in the intrinsic pathway. Intrin-SI reagent is sensitive to heparin and lupus anticoagulant plasmas.

Calcium Chloride Solution $0 . 0 2 \mathrm { M } \left( \mathrm { C a C l } _ { 2 } \right)$ is intended for quantitative use with ellagic acid (Intrin-EA) or silicone particulate activators (Intrin-SI) in performing the Activated Partial Thromboplastin Time (APTT) on citrated plasma.

Fibrinogen Plasma Controls Normal and Low are quantitative control plasma intended for use in the quality control of fibrinogen assays.

Fibrinogen Buffer is intended for use with fibrinogen controls for quantitative determine of fibrinogen in plasma.

Thrombin Reagent is intended for use in the quantitative determination of fibrinogen in plasma samples.

Fibrinogen Assay Set, containing a complete set of Normal Fibrinogen Control $( 2 0 0 { - } 4 0 0 \ \mathrm { m g / d l } )$ , Thrombin Reagent $[ 1 0 0 \mathrm { I U / m l } ]$ , and Fibrinogen Buffer, is intended for use in the quantitative determination of fibrinogen in plasma samples.

Heparin Control Level 1 and Level 2 are intended as a quality control of the Activated Partial Thromboplastin Time (APTT) during heparin monitoring.

2. Indication(s) for use: Same as above.

3. Special conditions for use statement(s): Not applicable.

4. Special instrument requirements: Not applicable.

# I. Device Description:

Stasis 1, 2, and 3 are liquid controls processed from human plasma collected with $3 . 2 \%$ sodium citrate anticoagulant, with stabilizers and buffers added. The product is supplied in $1 0 ~ \mathrm { m l }$ bottles.

Serathan-A and Serathan-B reagents are liquid products prepared from rabbit brain tissue, calcium, sodium azide, salts and stabilizers. The reagents are supplied in $2 0 ~ \mathrm { m l }$ bottles.

Intrin-SI reagent is prepared from rabbit brain phospholipids, kaolin, sodium azide, salts and stabilizers. The reagent is supplied in $1 0 ~ \mathrm { m l }$ bottles.

Intrin-EA reagent is prepared from rabbit brain phospholipids, ellagic acid, sodium azide, salts, and stabilizers. The reagent is supplied in $1 0 \mathrm { m l }$ bottles.

Calcium Chloride $\mathbf { ( C a C l } _ { 2 } )$ is composed of $0 . 2 2 2 \% \mathrm { M }$ calcium chloride and $0 . 1 \%$ sodium azide. This reagent is supplied in $1 0 ~ \mathrm { m l }$ bottles

Fibrinogen Plasma Controls Normal and Low are liquid controls prepared from human plasma collected with $3 . 2 \%$ sodium citrate anticoagulant, with stabilizers and buffers. This control is supplied in $1 0 ~ \mathrm { m l }$ bottles.

Fibrinogen Buffer consists of $1 . 3 \%$ TAPSO Buffer, $0 . 1 \%$ sodium chloride, $0 . 1 \%$ sodium azide, and stabilizers; $\mathrm { p H } 7 . 3 5 { \pm } 0 . 0 5$ . This buffer is supplied in $1 0 0 ~ \mathrm { m l }$ bottle

Thrombin reagent is a liquid bovine thrombin containing $1 0 0 \mathrm { \ : I U / m l }$ , $0 . 1 \%$ sodium azide, and stabilizers. This reagent is supplied in $1 0 \mathrm { m l }$ bottles.

Fibrinogen Assay Set consists of: Normal Fibrinogen Control $2 0 0 { - } 4 0 0 \ \mathrm { m g / d l }$ prepared from human plasma collected with $3 . 2 \%$ sodium citrate anticoagulant with stabilizers and buffers, Thrombin Reagent $[ 1 0 0 \mathrm { I U / m l } ]$ ) which is liquid bovine thrombin, and Fibrinogen Buffer (TAPSO buffer in saline, $\mathrm { p H } 7 . 3 5 { \pm } 0 . 0 5$ , with $0 . 1 \%$ sodium azide as a preservative. This assay set contains $1 \mathrm { ~ x ~ } 5 \mathrm { ~ m l }$ bottle of Normal

Fibrinogen Control, $1 \mathrm { ~ x ~ } 5 \mathrm { ~ m l }$ bottle of Thrombin Reagent and $4 \mathrm { ~ x ~ } 1 0 0 \mathrm { ~ m l }$ bottles of Fibrinogen Buffer.

Heparin Control Level 1 is a liquid preparation of citrated human plasma containing, $0 . 2 5 \mathrm { U } / \mathrm { m l }$ sodium heparin (derived from porcine intestine), sodium azide, stabilizers and buffers. The product is supplied in $1 0 ~ \mathrm { m l }$ bottles.

Heparin Control Level 2 a liquid preparation of citrated human plasma containing, $0 . 3 5 \mathrm { U } / \mathrm { m l }$ sodium heparin (derived from porcine intestine), sodium azide, stabilizers and buffers. The product is supplied in $1 0 ~ \mathrm { m l }$ bottles.

# J. Substantial Equivalence Information:

1. Predicate device name(s):

Pacific Hemostasis Coagulation Control Level I, Pacific Hemostasis Coagulation Control Level II, Pacific Hemostasis Coagulation Control Level III

Pacific Hemostasis Thromboplastin-DS Reagent, Pacific Hemostasis Thromboplastin-D Reagent

Pacific Hemostasis APTT-LS, Pacific Hemostasis Kontact

Pacific Hemostasis Fibrinogen Normal and Low Control, Pacific Hemostasis, Thrombin Reagent, Pacific Hemostasis Heparin Control I

2. Predicate 510(k) number(s):

K984129, K984130, K984131   
K940082, K994100   
K891337, K023362   
K832520, K800826,   
K992278, K992279   
K970645

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Stasis 1</td><td rowspan=1 colspan=1>Pacific Hemostasis Level I</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>As a quality control tomonitor performance of PT,APTT and Fibrinogen in thenormal range.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Range (Mechanical)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>PT</td><td rowspan=1 colspan=1>11.5-11.8 sec</td><td rowspan=1 colspan=1>11.4-11.9 sec</td></tr><tr><td rowspan=1 colspan=1>APTT</td><td rowspan=1 colspan=1>29.3-29.7 sec</td><td rowspan=1 colspan=1>28.0-28.8 sec</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen</td><td rowspan=1 colspan=1>301-313 g/dl</td><td rowspan=1 colspan=1>297-315 g/dl</td></tr></table>

<table><tr><td rowspan=1 colspan=4>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=2>Stasis 1</td><td rowspan=1 colspan=1>Pacific Hemostasis Level I</td></tr><tr><td rowspan=1 colspan=4>Differences</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=2>Liquid human citratedplasma</td><td rowspan=1 colspan=1>Lyophilized human citratedplasma</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=2>12 months at ≥ -2°C,30 days at 2-8°C</td><td rowspan=1 colspan=1>35 months at 2-8°C,lyophilized, 8 hours at 2-8°C ,rehydrated</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=2>≥ -2C</td><td rowspan=1 colspan=1>2-8°C</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Stasis 2</td><td rowspan=1 colspan=1>Pacific Hemostasis Level II</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>As a quality control tomonitor performance of PTand APTT in the moderateabnormal range.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Range (Mechanical)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>PT</td><td rowspan=1 colspan=1>19.9-20.3 sec</td><td rowspan=1 colspan=1>19.7-20.8 sec</td></tr><tr><td rowspan=1 colspan=1>APTT</td><td rowspan=1 colspan=1>54.9-56.6 sec</td><td rowspan=1 colspan=1>53.9-56.2 sec</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>Liquid human citrated plasma</td><td rowspan=1 colspan=1>Lyophilized human citratedplasma</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>12 months at ≥ -2°C,30 days at 2-8°</td><td rowspan=1 colspan=1>35 months at 2-8°C,lyophilized, 8 hours at 2-8°C ,rehydrated</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>≥-2C</td><td rowspan=1 colspan=1>2-8°C</td></tr></table>

<table><tr><td rowspan=1 colspan=4>Similarities</td></tr><tr><td rowspan=1 colspan=2>Item</td><td rowspan=1 colspan=1>Stasis 3</td><td rowspan=1 colspan=1>Pacific Hemostasis Level II</td></tr><tr><td rowspan=1 colspan=2>Intended Use</td><td rowspan=1 colspan=1>As a quality control tomonitor performance of PTand APTT in the highabnormal range.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=2>Expected Range (Mechanical)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>PT</td><td rowspan=1 colspan=1>32.0-33.0 sec</td><td rowspan=1 colspan=1>31.4-33.6 sec</td></tr><tr><td rowspan=1 colspan=2>APTT</td><td rowspan=1 colspan=1>69.4-71.5 sec</td><td rowspan=1 colspan=1>68.8-71.4</td></tr><tr><td rowspan=1 colspan=4>Differences</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=2>Liquid human citratedplasma</td><td rowspan=1 colspan=1>Lyophilized human citratedplasma</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=2>12 months at ≥ -2°C30 days at 2-8°C</td><td rowspan=1 colspan=1>35 months at 2-8°C, lyophilized8 hours at 2-8°C , rehydrated</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=2>≥-2oC</td><td rowspan=1 colspan=1>2-8C</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Serathan-A PT</td><td rowspan=1 colspan=1>Pacific HemostasisThromboplastin-DS</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For the quantitativedetermination of PT ofcoagulation abnormalities inthe extrinsic pathway;highly sensitive</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>Liquid Rabbitthromboplastin</td><td rowspan=1 colspan=1>Lyophilized Rabbitthromboplastin</td></tr><tr><td rowspan=1 colspan=1>International Sensitivity Index(ISI)</td><td rowspan=1 colspan=1>1.0-1.2</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=1>PT, Fibrinogen, Factors II,V, VII, X</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>12 months at ≥ -2°C30 days at 2-8°</td><td rowspan=1 colspan=1>30 months at 2-8°C, lyophilized7 days at 2-8°C, rehydrated</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>≥-2C</td><td rowspan=1 colspan=1>2-8°C</td></tr></table>

<table><tr><td rowspan=1 colspan=4>Similarities</td></tr><tr><td rowspan=1 colspan=2>Item</td><td rowspan=1 colspan=1>Serathan-B PT</td><td rowspan=1 colspan=1>Pacific HemostasisThromboplastin-D</td></tr><tr><td rowspan=1 colspan=2>Intended Use</td><td rowspan=1 colspan=1>For the quantitativedetermination of PT forcoagulation abnormalities inthe extrinsic pathway;moderately sensitive</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=2>Composition</td><td rowspan=1 colspan=1>Liquid Rabbitthromboplastin</td><td rowspan=1 colspan=1>Lyophilized Rabbitthromboplastin</td></tr><tr><td rowspan=1 colspan=2>International Sensitivity Index(ISI)</td><td rowspan=1 colspan=1>1.5-1.7</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=2>Assay Factors</td><td rowspan=1 colspan=1>PT, Fibrinogen, Factors II,V, VII, X</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=4>Differences</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=2>12 months at ≥ -2°C30 days at 2-8°C</td><td rowspan=1 colspan=1>30 months at 2-8°C, lyophilized7 days at 2-8°C, rehydrated</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=2>≥-2C</td><td rowspan=1 colspan=1>2-8°C</td></tr></table>

<table><tr><td colspan="3">Similarities</td></tr><tr><td>Item</td><td>Intrin-EA APTT Reagent</td><td>Pacific Hemostasis APTT-LS Same</td></tr><tr><td>Intended Use</td><td>For the quantitative determination of APTT for coagulation abnormalities in the intrinsic pathway; sensitive to mild coagulopathies.</td><td></td></tr><tr><td>Composition</td><td>Liquid Rabbit thromboplastin with ellagic acid activator</td><td>Same</td></tr><tr><td>Assay Factors</td><td>APTT, Heparin, Factors VIII IX,XI,XII</td><td>Same</td></tr><tr><td colspan="3" rowspan="1">Item                  Intrin-EA APTT Reagent    Pacific Hemostasis APTT-LS</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Stability</td><td colspan="1" rowspan="1">12 months at ≥ -2°C30 days at 2-8°C</td><td colspan="1" rowspan="1">22 months at 2-8°C, lyophilized30 days at 2-8°C, rehydrated</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">≥-2°C</td><td colspan="1" rowspan="1">2-8°C</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Intrin-SI APTT Reagent</td><td rowspan=1 colspan=1>Pacific Hemostasis Kontact</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For the quantitativedetermination of APTT forcoagulation abnormalities inthe intrinsic pathway;sensitive to heparin andlupus anticoagulantplasmas.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>Liquid Rabbitthromboplastin with kaolinactivator</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=1>APTT, Heparin, FactorsVIII, IX,XI,XII</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>12 months at ≥ -2°C30 days at 2-8°</td><td rowspan=1 colspan=1>12 months at 2-8°C, lyophilized30 days at 2-8°C, rehydrated</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>≥-2°C</td><td rowspan=1 colspan=1>2-8C</td></tr></table>

<table><tr><td colspan="4" rowspan="1">Similarities</td></tr><tr><td colspan="2" rowspan="1">Item</td><td colspan="1" rowspan="1">Fibrinogen Control</td><td colspan="1" rowspan="1">Pacific Hemostasis Fibrinogen</td></tr><tr><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">Plasma (Normal and Low)</td><td colspan="1" rowspan="1">Assay</td></tr><tr><td colspan="2" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For use in the qualitycontrol of fibrinogen assays.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="2" rowspan="1">Expected Range (Mechanical)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">EY</td></tr><tr><td colspan="2" rowspan="1">Normal</td><td colspan="1" rowspan="1">301-313</td><td colspan="1" rowspan="1">297-315</td></tr><tr><td colspan="2" rowspan="1">Low</td><td colspan="1" rowspan="1">97-103</td><td colspan="1" rowspan="1">97-104</td></tr><tr><td colspan="4" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Composition</td><td colspan="2" rowspan="1">Liquid human citratedplasma</td><td colspan="1" rowspan="1">Lyophilized human citratedplasma</td></tr><tr><td colspan="1" rowspan="1">Stability</td><td colspan="2" rowspan="1">12 months ≥ -2°C30 days at 2-8°C</td><td colspan="1" rowspan="1">24 months at 2-8°C, lyophilized16 days at 2-8°C, rehydrated</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="2" rowspan="1">≥-2oC</td><td colspan="1" rowspan="1">2-8°C</td></tr><tr><td colspan="2" rowspan="1">Item</td><td colspan="1" rowspan="1">Thrombin Reagent)</td><td colspan="1" rowspan="1">Pacific Hemostasis ThrombinReagent</td></tr><tr><td colspan="2" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For thrombin to convertfibrinogen in thequantitative determinationof fibrinogen in plasmasamples.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="2" rowspan="1">Expected Range (Mechanical)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1"></td><td colspan="1" rowspan="1">118-120 IU/ml</td><td colspan="1" rowspan="1">118-120 IU/ml</td></tr><tr><td colspan="3" rowspan="1">Differences</td><td colspan="1" rowspan="1">cYanmaGellowb</td></tr><tr><td colspan="1" rowspan="1">Composition</td><td colspan="2" rowspan="1">Liquid bovine thrombin</td><td colspan="1" rowspan="1">Lyophilized bovine thrombin</td></tr><tr><td colspan="1" rowspan="1">Stability</td><td colspan="2" rowspan="1">12 months at ≥ -2°C30 days at 2-8°C</td><td colspan="1" rowspan="1">28 months at 2-8°C, lyophilized1 day at 2-8°C, rehydrated</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="2" rowspan="1">≥-2°C</td><td colspan="1" rowspan="1">2-8°C</td></tr></table>

<table><tr><td rowspan=1 colspan=4>Similarities</td></tr><tr><td rowspan=1 colspan=2>Item</td><td rowspan=1 colspan=1>Heparin Control Plasma(Level 1 and Level 2)</td><td rowspan=1 colspan=1>Pacific Hemostasis Heparin(Control Level 1 and Level 2)</td></tr><tr><td rowspan=1 colspan=2>Intended Use</td><td rowspan=1 colspan=1>For use in the qualitycontrol of APTT duringheparin monitoring, yieldingslightly abnormal range forLevel 1 (0.25 U/ml) andmarked abnormal range forLevel 2 (0.35 U/ml)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=2>Expected Range (Mechanical)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Level 1</td><td rowspan=1 colspan=1>45.2-48.5 sec</td><td rowspan=1 colspan=1>44.8-49.1 sec</td></tr><tr><td rowspan=1 colspan=2>Level 2</td><td rowspan=1 colspan=1>62.4-64.6 sec</td><td rowspan=1 colspan=1>60.1-65.2 sec</td></tr><tr><td rowspan=1 colspan=4>Differences</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=2>Liquid human citratedplasma with heparin</td><td rowspan=1 colspan=1>Lyophilized human citratedplasma with heparin</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=2>12 months at ≥ -2°C30 days at 2-8°C</td><td rowspan=1 colspan=1>36 months at 2-8°C, lyophilized8 hours at 2-8°C, rehydrated</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=2>≥-2C</td><td rowspan=1 colspan=1>2-8C</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

H47-A One Stage Prothrombin Time (PT) Test and Activated Partial Activated Thromboplastin (APTT) Test; Approved Guideline, NCCLS

H21-A3 Collection, Transport and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays; Approved Guideline; Third Edition, NCCLS

H30-A2 Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline - Second Edition, NCCLS

WHO Expert Committee on Biological Standardization 28th Report: WHO Technical Series 610, World Health Organization, Geneva, pp. 14-15 and 45-51; 1977.

# L. Test Principle:

Stasis 1 (Normal), Stasis 2 (Moderate Abnormal), and Stasis 3 (High Abnormal):

The use of quality controls is essential for assuring quality in coagulation testing. Stasis 3 and a normal control, such as Stasis 1, are an integral part of a complete quality assurance program.

Serathan-A and Serathan-B reagents: The PT is used as a screen and quantitative test for coagulation factors in the extrinsic and common pathways. Patients with acquired or congenital disorders that reduce the activities of Fibrinogen and Factors II, V, VII, and X will be prolonged in this test. The PT is used to monitor oral anticoagulation therapy. The one step PT measures the clotting time of plasma after adding a source thromboplastin and calcium. The recalcification of plasma with thromboplastin generates activated FXa. FXa in turn activates Prothrombin, which converts fibrinogen to an insoluble fibrin clot.

Intrin-EA and Intrin-SI reagents: The APTT is an established tool as a quantitative test for the intrinsic coagulation factors. It is a simple versatile test which is sensitive to functional deficiencies of factors VIII, IX, XI, and XII. The APTT is performed by adding reagent containing a plasma activator and phospholipid to the test specimen.

Thrombin Control Normal and Low, Thrombin Reagent: The thrombin clotting time fibrinogen assay is based on the method described by Clauss. 1 In the presence of high concentrations of thrombin, the time required for clot formation in dilute plasma is inversely proportional to the fibrinogen concentrations.

Heparin Control Plasma Level 1 and 2: The anticoagulant heparin is used in the treatment of various thrombosis disorders, and for the prevention of thrombin formation during surgery. There are a number of assays available for the clinical laboratory to monitor heparin therapy. A critical component in these assays is the use of quality control plasmas.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Stasis 1 Control is formulated to have PT, APTT, and Fibrinogen values in the normal range. The reproducibility of three lot of the control, a run-run $( \mathrm { n } { = } 1 8 0 )$ singlicate assays, produced a coefficient of variations of $< 1 \%$ for the PT, $< 1 \%$ for the APTT, and $< 1 \%$ for Fibrinogen assays. This study was performed on the BBL Fibrometer.

Stasis 2 Control is formulated to have PT, APTT values in the moderate abnormal range. The reproducibility of three lots of the control, a run-run $\mathrm { ( n { = } 1 8 0 }$ ) singlicate assays, produced a coefficient of variations of $< 1 \%$ for the

PT, $< 1 . 5 \%$ for the APTT assays. This study was performed on the BBL Fibrometer.

Stasis 3 Control is formulated to have PT, APTT values in the strongly abnormal range. The reproducibility of three lots of the control, a run-run $\mathrm { ( n { = } 1 8 0 ) }$ singlicate assays, produced a coefficient of variations of $< 1 \%$ for the b $\mathrm { { T } , < 1 . 6 \% }$ for the APTT assays. This study was performed on the BBL Fibrometer.

Serathan-A and Serathan-B: Both reagents were assayed by testing the reagent against three lots each of normal and abnormal control plasma, in singlicate assays, on the BBL Fibrometer. A summary of the results follow:

# Serathan-A

<table><tr><td rowspan="2"></td><td colspan="3">Level 1</td><td colspan="2">Level 2</td><td colspan="2">Level 3</td></tr><tr><td>n</td><td>run(sec)</td><td>% CV</td><td>n run(sec)</td><td>% CV</td><td>n run(sec)</td><td>% CV</td></tr><tr><td>Within-run</td><td>60</td><td>12.66</td><td>0.89%</td><td>60 36.45</td><td>1.09%</td><td>60 61.60</td><td>1.25%</td></tr><tr><td>Run-run</td><td>60</td><td>12.67</td><td>0.88%</td><td>60 36.47</td><td>.08%</td><td>60 61.13</td><td>1.28%</td></tr></table>

# Serathan-B

<table><tr><td rowspan="2"></td><td colspan="3">Level 1</td><td colspan="3">Level 2</td><td colspan="2">Level 3</td></tr><tr><td>n</td><td>run(sec)</td><td>% CV</td><td>n</td><td>run(sec)</td><td>% CV</td><td>run(sec)</td><td>% CV</td></tr><tr><td>Within-run</td><td>60</td><td>11.57</td><td>0.80%</td><td>60</td><td>21.17</td><td>1.27%</td><td>60 32.51</td><td>1.42%</td></tr><tr><td>Run-run</td><td>60</td><td>11.56</td><td>0.75%</td><td>60</td><td>21.13</td><td>1.22%</td><td>60 32.51</td><td>1.44%</td></tr></table>

Intrin-EA was assayed by testing the reagent against normal and abnormal control plasmas, in singlicate assays, on the BBL Fibrometer. A Summary of the results follows:

<table><tr><td rowspan="2"></td><td colspan="3">Level 1</td><td rowspan="2"></td><td colspan="2">Level 2</td><td rowspan="2"></td><td colspan="2">Level 3</td></tr><tr><td>n</td><td>run(sec)</td><td>% CV</td><td>run(sec)</td><td>% CV</td><td>run(sec)</td><td>% CV</td></tr><tr><td>Within-run</td><td>60</td><td>29.01</td><td>0.51%</td><td>n 60</td><td>48.03</td><td>0.41%</td><td>n 60</td><td>67.74</td><td>0.73%</td></tr><tr><td>Run-run</td><td>60</td><td>29.03</td><td>0.60%</td><td>60</td><td>47.52</td><td>0.44%</td><td>60</td><td>67.74</td><td>0.71%</td></tr></table>

Intrin-SI was assayed by testing normal and abnormal plasmas on the BBL Fibrometer. A Summary of the results follows:

<table><tr><td colspan="4">Level 1</td><td colspan="2">Level 2</td><td colspan="2">Level 3</td><td colspan="2"></td></tr><tr><td>n</td><td>run(sec)</td><td></td><td>% CV n</td><td></td><td>run(sec) % CV</td><td>n</td><td>run(sec)</td><td>% CV</td><td></td></tr><tr><td>Within-run</td><td>60</td><td>29.51</td><td>0.29%</td><td></td><td>60 55.75</td><td>0.74%</td><td>60</td><td>70.49</td><td>0.75%</td></tr><tr><td>Run-run</td><td>60</td><td>29.51</td><td>0.29%</td><td></td><td>60 55.75</td><td>0.75%</td><td>60</td><td>70.49</td><td>0.75%</td></tr></table>

Fibrinogen Control Low plasma samples were tested on the BBL

Fibrometer, yielding a within-run and run-run precision of $0 . 6 0 \%$ CV and $0 . 5 8 \%$ CV, respectively.

Fibrinogen Control Normal plasma samples were tested on the BBL Fibrometer, yielding a within-run and run-run precision of $0 . 5 6 \%$ CV and $0 . 5 7 \%$ CV, respectively.

Heparin Control Level 1 Plasma as abnormal APTT control, within-run precision studies performed on the BBL Fibrometer using Intrin-SI reagent yielded CV’s of $1 . 8 2 \%$ , and a $1 . 7 7 \%$ CV for run-run assays.

Heparin Control Level 2 Plasma as abnormal APTT control, within-run precision studies performed on the BBL Fibrometer using Intrin-SI reagent yielded CV’s of $1 . 9 2 \%$ , and a $1 . 8 1 \%$ CV for run-run assays.

Thrombin Reagent: Precision of the Normal and Low Fibrinogen Control result is dependent on many factors, such as the instrument, technique and the reagent used. A 1:6 and 1:8 dilutions of 3 lots of the Normal and Low Fibrinogen Control respectively, were made and assayed in singlicate on the BBL Fibrometer. A summary of the results follow:

<table><tr><td>Control</td><td>n</td><td>within-run</td><td>n</td><td>run-run</td></tr><tr><td>Normal</td><td>60</td><td>0.56% CV</td><td>180</td><td>0.57% CV</td></tr><tr><td>Low</td><td>60</td><td>0.60% CV</td><td>180</td><td>0.58% CV</td></tr></table>

# b. Linearity/assay reportable range:

Serathan-A Reportable Range/Linearity: A linearity study, assayed on the BBL Fibrometer, of Intrin-EA to measure warfarin in 18 plasma samples of 0- $5 \mathrm { { U / m l } }$ , yielded a linearity range of 12.1 –41.9 seconds.

Serathan-B reagents Reportable Range/Linearity: A linearity study, assayed on the BBL Fibrometer, to measure warfarin in 18 plasma samples of $0 { - } 5 \ \mathrm { U } / \mathrm { m l }$ , yielded a linearity range of $1 1 . 6 - 3 6 . 2 $ seconds.

Intrin-EA A Reportable Range/Linearity: linearity study, assayed on the BBL Fibrometer, of Intrin-EA to measure heparin in 18 plasma samples of 0-5 $\mathrm { U } / { \mathrm { m l } }$ , yielded a linearity range of 29.0 –70.7 seconds.

Intrin-SI Reportable Range/Linearity: A linearity study, assayed on the BBL Fibrometer, of Intrin-SI to measure heparin in18 plasma samples of 0-5 $\mathrm { U } / { \mathrm { m l } }$ , yielded a linearity range of 29.8 - 106.3 seconds.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Expected Values:

Stasis Control 1, 2, 3 When all levels of Stasis controls were evaluated on the BBL Fibrometer, the following results were obtained:   

<table><tr><td></td><td>Serathan-B (ISI=1.58)</td><td>Serathan-A (ISI=1.20)</td></tr><tr><td>Stasis 1</td><td>11.5-11.9</td><td>12.4-12.8 sec</td></tr><tr><td>Stasis 2</td><td>20.4-22.0</td><td>31.6-33.4 sec</td></tr><tr><td>Stasis 3</td><td>31.6-33.4 sec</td><td>60.7-62.3 sec</td></tr></table>

Intrin-EA 28.6-29.4 sec 46.0-47.0 sec 63.8-65.8 sec

Intrin-SI Stasis 1 29.3-29.7 0 Stasis 2 55.0-56.6 sec Stasis 3 69.4-71.6 sec Fibrinogen, Normal Stasis 1 $2 9 9 - 3 0 3 \ \mathrm { m g / d l }$

# Fibrinogen Control Low

Three lots were evaluated in singlicate on the BBL Fibrometer $\mathrm { ( n { = } 1 8 0 }$ ), the run-run mean fibrinogen level of $9 9 \mathrm { m g / d l }$ and ${ \bf a } \pm 2 { \bf S } \mathrm { D }$ range of 98-100 $\mathrm { m g / d l }$ . Actual values recovered depend on the instrument and reagent used.

# Fibrinogen Control Normal

Three lots were evaluated in singlicate on the BBL Fibrometer $\mathrm { ( n { = } 1 8 0 }$ ), the run-run mean fibrinogen level was $3 0 1 \mathrm { m g / d l }$ and a $: \pm 2 \mathrm { S D }$ range of 300-302 mg/dl Actual values recovered depend on the instrument and reagent used.

Heparin Control Plasma Level 1 was assayed on the BBL Fibrometer produced a mean APTT clotting time of 46.9 seconds and ${ \bf a } \pm 2 { \bf S } \mathrm { D }$ range of 45.1-48.7 seconds.

Heparin Control Plasma Level 2 was assayed on the BBL Fibrometer produced a mean APTT clotting time of 63.5 seconds and ${ \bf a } \pm 2 { \bf S } \mathrm { D }$ range of 61.2-65.8 seconds.

Stability: A Real Time Stability study for all coagulation controls and reagents was performed for 30 days at $- 2 ^ { \circ } \mathrm { C }$ and $4 \mathrm { ^ { o } C }$ . Results showed not loss of activity. Real time studies will be on going.

d. Detection limit: Not Applicable.   
e. Analytical specificity: Not Applicable.   
f. Assay cut-off: Not Applicable.

2. Comparison studies:

a. Method comparison with predicate device:

Serathan-A and Serathan-B was tested against the predicate with 120 adult normal and coumadin patient samples, in singlicate assay. Results:

Serathan A $\begin{array} { l l } { { \mathrm {  ~ { \cal ~ r } = 0 . 9 9 9 } } } & { { \mathrm {  ~ { \cal ~ y } = 0 . 9 4 8 x + 0 . 6 2 0 } } } \\ { { \mathrm {  ~ { \cal ~ r } = 0 . 9 9 6 } } } & { { \mathrm {  ~ { \cal ~ y } = 0 . 9 8 9 x + 0 . 0 3 9 } } } \end{array}$ Serathan-B

Intrin-EA and Intrin- SI: Studies were performed against another thromboplastin reagent by performing APTT testing on 120 adult normal and heparinized patient samples, and 10 lupus anticoagulant plasma samples in singlicate assay, on the BBL Fibrometer.

# Results:

Intrin-EA $\mathrm { r } = 0 . 9 9 6$ $\mathrm { y } = 1 . 0 2 2 \mathrm { x } + 1 . 2 9 3$ Lupus Study $\mathrm { r } = 0 . 9 7 9$ $\mathrm { y } = 1 . 0 3 7 \mathrm { x } \mathrm { - } 4 . 3 6 3$

Intrin-SI $\mathrm { r } = 0 . 9 9 8$ $\mathrm { y } = 1 . 0 3 2 \mathrm { x } + 0 . 1 5$ Lupus Study $\mathrm { r } = 0 . 8 4 4$ $\mathrm { y } = 1 . 0 3 3 \mathrm { x } - 4 . 7 6$

b. Matrix comparison: Not Applicable.

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable.   
b. Clinical specificity: Not Applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable.

4. Clinical cut-off: Not Applicable.

5. Expected values/Reference range:

Serathan-B was evaluated on a normal population, the following results were obtained:

Instrument PT Mean (sec) Range (± 2SD) N ACL Advance 11.5 10.9 –12.1 60

Serathan-A was evaluated on a normal population, the following results were obtained:

Intrin-EA was evaluated on 60 normal adult patients using the BBL Fibrometer, the following results were obtained.

<table><tr><td></td><td>PT Mean (sec)</td><td>Range (± 2SD)</td><td>N</td></tr><tr><td>Photo-optical</td><td>29.0</td><td>28.7 29.3</td><td>60</td></tr><tr><td>Mechanical</td><td>29.0</td><td>28.5 29.5</td><td>60</td></tr></table>

These values should only be used as a guideline. Each laboratory should establish a Normal Reference Range

Intrin-SI was evaluated on 60 normal adult patients, the following results were obtained.

<table><tr><td></td><td>PT Mean (sec)</td><td>Range (± 2SD)</td><td>N</td></tr><tr><td>Photo-optical</td><td>29.5</td><td>29.3 29.6</td><td>60</td></tr><tr><td>Mechanical</td><td>29.5</td><td>29.3 29.6</td><td>60</td></tr></table>

# Thrombin Reagent

Laboratories should establish a normal control interval for fibrinogen measurement. The referenced normal control is $2 0 0 { - } 4 0 0 \ \mathrm { m g / d l }$ .

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.